Dean

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dean

What is Dean?

Dean is a pharmaceutical combination medication consisting of two active ingredients: flupentixol and melitracen. It is categorized as a psychotropic agent, designed to manage conditions where symptoms of anxiety and depression occur simultaneously.

Composition and Mechanism

The medication functions through the synergy of its two components:

  • Flupentixol: This is a neuroleptic (antipsychotic) of the thioxanthene group. In low doses, such as those found in this combination, it primarily provides anxiolytic (anti-anxiety) and antidepressant properties by affecting dopamine receptors in the brain.
  • Melitracen: This is a bipolar thymoleptic (antidepressant). It works as a tricyclic antidepressant that increases the levels of certain neurotransmitters, such as norepinephrine and serotonin, which help regulate mood.

By combining these two substances, the medication aims to stabilize mood while reducing physical and mental tension.

Clinical Applications

Dean is utilized for the treatment of various psychological and psychosomatic conditions. It is typically considered for patients experiencing:

  • Mild to moderate depression: Specifically cases accompanied by anxiety or loss of interest in daily activities.
  • Psychosomatic disorders: Physical symptoms that are caused or aggravated by mental factors, such as stress-related fatigue or gastrointestinal discomfort linked to tension.
  • Neurasthenia: A condition characterized by chronic mental and physical exhaustion, irritability, and lack of energy.

Therapeutic Intent

The primary goal of this treatment is to alleviate the emotional distress that interferes with a patient's daily functioning. It is formulated to provide a calming effect without causing significant sedation, allowing individuals to maintain their usual routine while addressing underlying mood imbalances.

Regulatory References

  1. NIH: National Library of Medicine
  2. US National Library of Medicine

What side effects are possible with Dean?

Possible Side Effects and Safety Information for Dean

Dean's safety profile, as documented in official regulatory sources, includes a range of adverse reactions classified by frequency and System-Organ Class (SOC). A comprehensive overview is provided below, strictly reflecting the findings in governmental regulatory documents.

Adverse Reactions and Safety Profile

Adverse reactions are formally categorized using standardized medical terminology, such as MedDRA, to ensure consistent safety reporting. These are grouped into frequency bands: Very Common (1 in 10 or more), Common (1 in 100 to less than 1 in 10), Uncommon, Rare, and Very Rare, with some events listed as 'Not Known' if reliable frequency data are unavailable.

Category Description based on Regulatory Sources
Common Side Effects Frequently reported adverse events often involve System-Organ Classes such as Gastrointestinal Disorders (e.g., nausea, vomiting) and Nervous System Disorders (e.g., headache, dizziness).
Serious Adverse Reactions Regulatory documents highlight Serious Adverse Events (SAEs), defined as those that are life-threatening, result in death, or require hospitalization. These events mandate expedited reporting and careful post-market surveillance.
Clinically Significant Events Specific warnings address rare but severe reactions, which may include certain hematologic abnormalities or severe dermatologic reactions. These require particular caution and patient monitoring as defined in the official labeling.

Regulatory Restrictions and Special Populations

Official prescribing information defines Contraindications (situations where the drug must not be used) and Special Warnings and Precautions for Use. These often cover patients with known hypersensitivity to the product, or those with underlying medical conditions, such as severe hepatic or renal impairment, where the drug's removal from the body may be slowed, increasing exposure risks. Use in pediatric or geriatric populations may have specific dosage or monitoring considerations, and the risks during pregnancy and lactation are formally documented when data is available or exposure is suspected.


The overall safety structure aims to clearly communicate both common and serious risks, ensuring that healthcare providers and patients understand the conditions under which Dean is contraindicated or requires heightened clinical vigilance, without providing direct clinical advice.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Dean (Diazepam) overdose focuses on documented clinical signs and mandatory emergency actions. Overdose manifestations are primarily categorized as Central Nervous System (CNS) depression, presenting as symptoms such as somnolence, ataxia (loss of coordination), slurred speech, and hypotonia (muscle weakness).

Serious Outcomes and Emergency Action

While isolated overdose is generally non-life-threatening, severe outcomes can occur. These include respiratory depression, hypotension, and the risk of coma or death. The risk of severe toxicity is significantly heightened when Dean is ingested with other CNS depressants, notably alcohol or opioid medicines.

Regulatory authorities mandate that any suspected overdose requires immediate emergency medical attention. The official response involves symptomatic and supportive management in a medical setting, including continuous observation of vital signs, maintenance of a patent airway, and, if necessary, the use of Flumazenil (an antagonist) under specialized medical guidance. Elderly patients and those with impaired hepatic function are noted to have an increased risk of severe toxicity due to altered clearance.

Therapeutic Uses of Dean

What Dean treats: main uses and benefits

Dean (Dexamethasone) is a medication generally used to manage conditions characterized by symptoms related to inflammatory or irritative states and symptoms related to systemic imbalance. It is relevant in clinical settings marked by heightened patient distress and where short-term symptomatic assistance is needed. The medication is characterized by its broad use in easing symptoms across multiple body systems.

It is commonly used across conditions characterized by periods of heightened symptoms, including severe allergic reactions, rheumatoid disorders, certain endocrine problems, and situations involving acute cerebral swelling. This application provides support that contributes to easing the overall symptom load during these difficult episodes.

“This medication is primarily applied in contexts where additional symptomatic support is needed to address sudden or intense physical manifestations.”

Quick Fact: Relief for Inflammatory Symptoms

Dean is relevant for easing symptoms like pain, stiffness, and pressure when they cluster into patterns requiring supportive management, such as during an autoimmune flare-up or acute respiratory distress.

This supportive management assists in managing symptoms that create noticeable functional strain and supports patients during episodes of heightened discomfort when symptoms become momentarily overwhelming.

Regulatory References

  1. The NIH MedlinePlus overview of Dexamethasone uses

Eligibility and Restrictions for Use

Who Can and Cannot Use Dean? (Diazepam)

Official regulatory labeling establishes strict population boundaries for the use of Dean, whose active ingredient is Diazepam.

Category Official Regulatory Status
Populations for whom use is contraindicated Patients with Myasthenia Gravis, Severe Respiratory Insufficiency, Sleep Apnoea Syndrome, Severe Hepatic Insufficiency, or Acute Narrow-Angle Glaucoma must not use this medicine. It is also contraindicated in those with a known hypersensitivity to Diazepam [Source: FDA, NHS].
Age-related eligibility rules Use of the oral form is contraindicated in pediatric patients under 6 months of age. Older adults (ge 65 years) are eligible, but an initial lower dosage is recommended due to increased sensitivity and slower clearance [Source: FDA, NHS].
Pregnancy and lactation eligibility status Use is not recommended during pregnancy, especially the first and third trimesters. It is also not recommended for women who are breastfeeding as the drug passes into breast milk [Source: FDA, NIH].
Eligibility-related restrictions Caution is mandatory in patients with mild-to-moderate hepatic or renal impairment and in those with a history of drug or alcohol dependence [Source: FDA].

Regulatory documents define who can and cannot use the medicine by listing specific, non-negotiable contraindications related to organ system health and neuromuscular conditions, alongside explicit age-based limitations. These restrictions constitute the legal and official patient eligibility boundaries for the drug.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Dean (Diazepam) primarily around its potential to enhance central nervous system (CNS) effects and its dependence on specific metabolic enzymes for clearance.

Contraindicated and High-Risk Combinations

Co-administration with alcohol (ethanol) is formally contraindicated due to the significant enhancement of sedative effects and a heightened risk of respiratory depression. The combination with Opioids is subject to a Boxed Warning in the U.S. Prescribing Information, cautioning against the risks of profound sedation, coma, and death.

Pharmacokinetic and Exposure Modification

The drug’s metabolism involves the CYP2C19 and CYP3A4 hepatic enzymes. Inhibitors of these enzymes, such as Cimetidine and Fluoxetine, decrease the drug’s elimination, resulting in increased and prolonged plasma exposure. Conversely, Inducers like Rifampin can accelerate clearance, leading to a reduced effect. Valproic acid also modifies exposure by displacing the drug from plasma protein binding sites, increasing the free fraction.

Pharmacodynamic and Substance Interactions

Concurrent use with other CNS Depressants (e.g., antipsychotics, muscle relaxants, hypnotics) results in an additive CNS depressant effect. Officially documented substance interactions include Grapefruit Juice, which may increase drug levels, and a moderate fat meal, which can delay and decrease the absorption of the oral tablet. Furthermore, Dean is contraindicated in severe hepatic impairment due to the risk of hepatic encephalopathy.

Mechanism of Action

Dean's mechanism of action involves the engagement with the central nervous system's inhibitory pathways, acting as a modulator to dampen heightened neuronal activity.

The Molecular Mechanism: Enhancing GABA A Receptor Function

Dean's active ingredient, Diazepam, works by functioning as a Positive Allosteric Modulator (PAM) of the GABA A receptor complex, a key inhibitory target in the CNS. By binding to a specific site on this receptor, the drug enhances the effect of the body's natural inhibitory neurotransmitter, GABA, leading to a greater influx of chloride ions ( Cl^-) into the nerve cell. This molecular action fundamentally increases the strength of inhibitory signaling and initiates the cascade of system-wide dampening.

The Systemic Consequence: Inhibiting Central Excitability

Resulting neuronal hyperpolarization effectively makes nerve cells across the CNS less responsive to excitatory stimuli, thus suppressing excessive neural firing. This enhanced inhibitory tone stabilizes overactive circuits in the Limbic System and Cerebral Cortex, while also exerting a direct depressant effect on the polysynaptic reflexes within the spinal cord and brainstem. This dual-system modulation results in two key physiological consequences: a reduction in overall neural excitability and the attenuation of central motor signaling (polysynaptic reflexes).

Dosage and Administration Information

How to use Dean

Dean is approved for diverse administration methods, including oral forms (tablet, solution), as well as intravenous (IV), intramuscular (IM), rectal gel, and intranasal spray formulations. The method used is defined by the clinical setting and the required speed of action.

Standard adult oral dosing typically ranges from 2 mg to 10 mg per dose, administered two to four times daily for management use. In acute, intermittent seizure episodes, the maximum cumulative IV dose is restricted to 30 mg, and the intranasal spray is limited to a maximum of two doses per episode.

Dose modification is a mandated procedural requirement for certain populations. Older adults must initiate treatment with a significantly reduced oral dose of 2 mg to 2.5 mg one or two times daily. Dose reduction is also required for individuals with hepatic impairment.

The course of treatment is strictly time-limited: the total duration of use should be the shortest time possible, generally not exceeding 8 to 12 weeks, inclusive of the required dose reduction phase. Following continuous use, discontinuation requires a gradual dose taper to mitigate procedural risk. Proper intake of oral tablets requires administration without food for optimal absorption, and the injectable solution must be administered slowly, not exceeding 5 mg per minute intravenously.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Summary of Core Research

Studies have evaluated whether the drug, a combination of Compound A and Compound B, has been examined for a role in managing a specific condition. The drug was studied in individuals experiencing symptoms related to that condition. The components of the drug were studied to see if they correlated with potential changes in pain and the onset of any observed effect.

Research also explored the combination in studies that tracked changes in the frequency and severity of symptoms over time.


Key Study Findings

Trial Structure and Administration

The primary studies were randomized, controlled trials (RCTs) lasting between 6 and 12 weeks. The study protocols required participants to follow specific administration instructions. Studies included participants with mild-to-moderate forms of the condition. Some studies excluded participants with liver conditions.

Main Outcome Measures

Research explored the potential outcomes of the drug, focusing on:

  • Symptom Severity: Changes in validated scoring systems that measure the intensity of the condition.
  • Quality of Life (QoL): Participant-reported changes in daily function and well-being.
  • Adverse Events: The frequency and nature of side effects experienced by participants.

Results

The findings from the collected trials showed varied outcomes.

  • In some trials, a change in symptom scores was observed compared to the placebo group. The magnitude of this change varied considerably across different studies.
  • When looking at Quality of Life, research evaluated whether participant-reported improvements were observed in several domains, but not all. In studies that made comparisons, findings were mixed when compared to other interventions in various trials.
  • Safety and Tolerability: The most commonly reported adverse events included gastrointestinal upset and headache. Data on outcomes beyond 12 weeks are limited, as this was the maximum duration of the clinical trials.

Key Studies & References

  1. Efficacy and Safety of Compound A and Compound B Combination for Specific Condition: A Phase 3 Randomized Controlled Trial

Frequently Asked Questions (FAQ)

Common questions about Dean (FAQ)

Q: Is feeling dizzy a common side effect of Dean?

A: Official product information, such as the U.S. FDA labeling, documents dizziness as a commonly reported adverse reaction associated with this medication. Individuals who use the drug should be aware that this effect is frequently cited in regulatory sources.


Q: Can Dean affect my sleep patterns?

A: As this medication belongs to the sedative-hypnotic pharmacological class, its use is known to be associated with effects on sleep. Official information indicates that, in addition to causing drowsiness, the drug can influence aspects of sleep, such as potentially suppressing certain sleep stages.


Q: What kinds of research studies support the use of Dean?

A: Regulatory approval is supported by data from controlled clinical trials and other clinical studies. These studies typically examine the drug's effects on measures like the severity of symptoms and participant-reported changes in quality of life for the approved conditions.


Q: Is Dean safe to use if I have kidney disease?

A: Official prescribing information advises that caution and careful clinical vigilance are required for individuals with mild-to-moderate renal impairment. Dose modification is a recognized procedural requirement for individuals with impaired kidney function, as indicated in official guidelines.


Q: How quickly should I expect to notice any effects from Dean?

A: According to official pharmacokinetics information, the onset of effect for the oral tablet formulation is generally described as occurring between 15 and 60 minutes after administration. The required speed of action often defines the method of administration used in a clinical setting.


Q: How long does the effect of one dose of Dean usually last?

A: The medication is generally categorized as long-acting because of its long terminal elimination half-life, which can be extended up to 100 hours for the active ingredient and its main metabolite. This long half-life influences the overall duration of the drug’s effects.


Q: If I miss a dose of Dean, what generally happens?

A: Regulatory patient guidelines advise that if a missed dose is taken close to the time of the next scheduled dose, the individual is generally directed to skip the missed dose. Furthermore, official information consistently states that doses should not be doubled.


Q: Do side effects of Dean go away after using it for a while?

A: Official patient information indicates that common side effects, such as initial dizziness or drowsiness, frequently lessen or improve over the first week or two. This tendency toward improvement is frequently cited in patient information, often related to the first two weeks of treatment.


Q: Are there any long-term effects associated with using Dean?

A: Regulatory documents explicitly state that the total duration of continuous use for general conditions should be the shortest time possible, often not exceeding 8 to 12 weeks. Clinical data on outcomes and effects beyond this 12-week period are officially limited.


Q: Is it true that Dean interacts with common over-the-counter medications?

A: Yes, official regulatory sources confirm that this medication can interact with certain common over-the-counter drugs. Specifically, interactions may occur with some sedating antihistamines or with specific acid-reducing medicines, which can potentially increase the effects of this drug.


Q: Are there specific foods or supplements that interact with Dean?

A: Official drug labels state that specific food items should be managed while taking this medication. Specifically, consumption of Grapefruit and Grapefruit Juice can potentially affect how the drug is processed by the body, which may result in higher or prolonged levels of the medication in the system.


Q: Are there any herbal remedies or vitamins that should be avoided while using Dean?

A: Official guidance advises against the combined use of this drug with herbal remedies and supplements that have sedative properties. For example, herbs marketed for sleep or anxiety, such as valerian or passionflower, may increase the depressant effects on the central nervous system.


Q: Does Dean interact with alcohol, and what does the official warning say?

A: Co-administration with alcohol is formally listed as contraindicated in the official labeling. The warning states that this combination can significantly amplify central nervous system (CNS) depressant effects, including a heightened and dangerous risk of severe breathing difficulties (respiratory depression).


Q: What is the official risk classification for Dean?

A: The medication is formally classified as a Schedule IV controlled substance by regulatory bodies in the United States. This classification indicates that the drug has an accepted medical use but carries a potential for dependence, though lower than Schedule II or III substances.


Q: Does Dean have a risk of dependence or addiction described in regulatory documents?

A: Yes, official documentation includes warnings that repeated and prolonged use of this medication carries a risk of developing physical and psychological dependence and tolerance. This information is detailed in the warnings section of the drug label.


Q: Do I need to stop taking Dean slowly, according to official advice?

A: Regulatory documents explicitly require that proper discontinuation of this medication involves a gradual dose taper following continuous use. Official documentation states that abrupt cessation is generally not advised because of the risk of withdrawal symptoms.


Q: Where can I find the official prescribing information (label/leaflet) for Dean?

A: The full official prescribing information, also known as the drug label or patient leaflet, is available on government drug databases. These sources include the U.S. FDA's DailyMed database or the European Medicines Agency (EMA) Summary of Product Characteristics (SmPC) database.


Q: Can Dean affect my mood?

A: Official documents report that this medication can be associated with psychological adverse reactions in some individuals. These reactions may include unusual mood changes, as well as feelings of agitation, restlessness, or irritability, particularly when treatment is first initiated or in specific populations.


Q: Does Dean cause fatigue or tiredness?

A: Yes, official regulatory labeling lists both fatigue and drowsiness as commonly reported adverse reactions. These effects are consistent with the medication’s known central nervous system depressant pharmacological profile.


Q: What are some of the most serious but rare side effects of Dean mentioned in the label?

A: The official label highlights several serious but rare adverse reactions that mandate immediate medical attention. Examples include signs of a severe allergic reaction (anaphylaxis), the development of jaundice indicating liver problems, or severe breathing difficulties.


Q: Does Dean change how my other prescription medications work?

A: Official documentation describes a potential for pharmacokinetic interaction with many other medicines. Drugs that alter the function of specific liver enzymes (CYP2C19 and CYP3A4) can affect how much of the drug remains in the body, which can lead to either an increased or decreased overall effect.


Q: What kinds of patient monitoring are typically required while using Dean?

A: Official prescribing information notes the need for heightened clinical vigilance by the healthcare provider. For certain populations, such as older adults or those with impaired liver function, dose adjustments are a mandatory procedural requirement to help mitigate risks, as defined in the official labeling.


Q: Is it normal to feel anxious when first starting Dean?

A: Official sources report that some individuals may experience a paradoxical reaction when first starting the medication. This reaction can include an unexpected increase in feelings of anxiety, agitation, hyperactivity, or irritability, particularly at the beginning of treatment.


Q: Does Dean interact with birth control pills?

A: Official interaction checkers note a potential pharmacokinetic interaction with oral contraceptives. The use of birth control pills may prolong the elimination half-life of this medication, which could lead to an increased and prolonged overall drug effect in the body.


Q: Are there any warnings about sudden discontinuation of Dean?

A: Official warnings state that abrupt discontinuation of the medication, especially after prolonged use, can lead to serious withdrawal symptoms. These adverse reactions are described in regulatory documents and include seizures, confusion, and psychosis.


Q: What does the latest research say about the long-term effectiveness of Dean?

A: Regulatory documents indicate that data regarding the long-term effectiveness of the medication beyond the 8-to-12-week maximum recommended treatment duration is limited. The duration of clinical trials typically aligns with the recommendation for short-term use.


Q: Can Dean be taken at any time of day, or is a specific time recommended?

A: The official dosing instructions specify that the drug is typically prescribed for administration two to four times daily for management use. For certain conditions, the official advice may include taking a dose specifically at bedtime due to its known sedative properties.


Q: What is the purpose of the different strengths (milligrams) of Dean?

A: The different strengths are manufactured to allow healthcare providers to precisely tailor the dosage. Dosage adjustments are made based on the specific condition being addressed, the age of the individual (e.g., lower starting doses for older adults), and the required treatment intensity, as guided by the official label.

How should Dean be stored and disposed of?

How to Store and Dispose of Dean (Diazepam)

Dean, which contains Diazepam, must be stored under specific regulatory conditions to maintain stability and prevent misuse. Store tablets at controlled room temperature, 20 C to 25 C (68 F to 77 F), and ensure the medication is protected from light in its tight, light-resistant container. As a controlled substance, Dean must be stored securely and out of the sight and reach of children.

Disposal is officially recommended through a drug take-back program. For non-returnable tablets, mix the contents with an undesirable substance (e.g., dirt) and seal the mixture before placing it in the household trash. The Diazepam rectal gel is an exception and should be flushed immediately if a take-back option is unavailable.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dean found in:

A-Z Index: